Medical Information Only. Consult your healthcare provider before considering clinical trial enrollment.

ClinicalTrials.gov 10 recruiting now early-phase tilt

Infection: early-phase trial registry

10 of 45 indexed Infection trials are currently recruiting, with more weight in Phase 1-2.

Corpus placement: #323 of 28,707 conditions by registered trial count.

45 US clinical trials · 10 currently recruiting · #323 of 28,707 conditions by registered trial count

Infection: 45 US clinical trials tracked, 10 recruiting.

Infection is the subject of 45 registered US clinical trials on ClinicalTrials.gov, 10 of them currently open to new participants. 5 are in Phase 3-4 (later-stage) and 10 in Phase 1-2 (earlier-stage). The most active sponsor is Brigham and Women's Hospital, running 4 of these trials.

Enrollment posture brief

Registry condition infection

OPEN 10 | RECR 22% | LATE 5 | EARLY 10 | RANK #323 | SPON 4

Nearest open-share peer: Acne (22% recruiting · 27 trials)

Asthma in Children66.7%Cannabis Use64.4%Cognitive Change55.6%Eosinophilic Esophagitis31.1%Infection (this)22%
Open-enrollment share among volume-matched conditions near Infection

Infection lists 10 open slots (22% of 45 indexed trials). Peers are matched on registered volume, not therapeutic-area browse lists. How peer matching works →

Key findings

What ClinicalTrials.gov does not surface for Infection on its own pages , computed from the registry mirror as of 2026-08-08. Each line carries its own denominator so it can be quoted as it stands.

  1. Infection is recruiting below its size-band peers.

    10 of 45 indexed trials (22.2%) are open to enrollment, against a 39.7% average across 762 conditions with 20-99 trials. The peer set uses the same ClinicalTrials.gov-derived counts as this page.

  2. Sponsorship of Infection trials is spread across many organizations.

    Brigham and Women's Hospital accounts for 4 of 45 trials (8.9%). 36 distinct sponsors appear on at least one study for this condition label.

  3. Typical Infection enrolment sits around 172 participants.

    Median target enrolment is 172 among the 42 trials that report a genuine target (sentinel values excluded). 16 of those (38.1%) plan for fewer than 100 participants.

  4. Infection splits between interventional and observational designs.

    30 interventional and 15 observational studies make up this index (66.7% interventional). Study type is sponsor-reported on ClinicalTrials.gov.

Phase 17Phase 23Phase 33Phase 42

Open and recent trials

45 total, page 1 of 1

RECRUITING NA 6,000 participants

Improving Implementation of Evidence-based Approaches and Surveillance to Prevent Bacterial Transmission and Infection

Trustees of Dartmouth College

NCT04600973

RECRUITING 4,200 participants

Biomarkers in Infection

Beth Israel Deaconess Medical Center

NCT02545478

RECRUITING NA 3,000 participants

Home Hospital for Suddenly Ill Adults

Brigham and Women's Hospital

NCT03524222

RECRUITING NA 2,000 participants

Microbial Cell-free Metagenomic Sequencing for Suspected Infections in Adult Immunocompromised Outpatients

Karius

NCT07110636

RECRUITING 400 participants

Diagnosis and Management of Inflammatory and Infectious Diseases

National Institute of Allergy and Infectious Diseases (NIAID)

NCT00557726

RECRUITING 380 participants

Persona Revision Knee System Outcomes

Zimmer Biomet

NCT04821154

RECRUITING NA 300 participants

BLOOM: Pragmatic Feasibility Trial

Mayo Clinic

NCT07287332

RECRUITING 300 participants

Effect of Alcohol and Drugs of Abuse on Immune Function in Critically Ill Patients With Respiratory Failure

University of Colorado, Denver

NCT02299921

RECRUITING NA 30 participants

Copper Supplementation in Cirrhosis

University of Washington

NCT07471542

RECRUITING Phase 1 25 participants

NADPH Oxidase Correction in mRNA-transfected Granulocyte-enriched Cells in Chronic Granulomatous Disease (CGD)

National Institute of Allergy and Infectious Diseases (NIAID)

NCT05189925

COMPLETED 6,300 participants

Systemic Immunosuppressive Therapy for Eye Diseases (SITE) Cohort Study

National Eye Institute (NEI)

NCT00116090

COMPLETED 1,055 participants

Evaluation of the Heparin Binding Protein Levels in Sepsis

Christiana Care Health Services

NCT02533011

COMPLETED 815 participants

Early Identification of SEPsis SIGNs in Emergency Department

BioMérieux

NCT04261621

COMPLETED Phase 4 563 participants

Antibiotic Prophylaxis for Transrectal Prostate Biopsy

Northwestern University

NCT01659866

COMPLETED Phase 3 524 participants

Study of a Topical Gentamicin-Collagen Sponge Along With Systemic Antibiotic in Infected Diabetic Foot Ulcers

Innocoll

NCT02447172

COMPLETED 500 participants

A Retrospective Review of Infections Usually Observed in Transplant Recipients

University of Pittsburgh

NCT00298077

COMPLETED 477 participants

Evaluation of Infection in Obstructing Urolithiasis

University of Texas Southwestern Medical Center

NCT04332861

COMPLETED NA 400 participants

Timing of Antibiotic Prophylaxis for Cesarean Deliveries

University of Florida

NCT00805545

COMPLETED Phase 1 400 participants

Triple Dye Plus Alcohol Versus Triple Dye Alone for Newborn Umbilical Cord Care

Penn State University

NCT00127699

COMPLETED 350 participants

Retrospective Analysis of Clinical Features in Ventriculoperitoneal Shunt Infectionsin Adults

University of Pittsburgh

NCT00524108

COMPLETED NA 330 participants

Effects of a Cranberry Beverage on Women With Recent History of Urinary Tract Infections

Ocean Spray Cranberries

NCT01776021

COMPLETED Phase 4 265 participants

MAKE IT CLEAN, Impact of Pocket Revision on the Rate of Infection and Other Complications in Patients Requiring Pocket Manipulation for Generator Replacement and/or Lead Replacement or Revision: A Prospective Randomized Study

Dhanunjaya Lakkireddy, MD, FACC

NCT00599261

COMPLETED NA 172 participants

Remote Physician Care for Home Hospital Patients

Brigham and Women's Hospital

NCT04080570

COMPLETED 166 participants

Identification of Gene and Protein Markers of Kidney Injury in Aminoglycoside-treated Children

Virginia Commonwealth University

NCT00308906

COMPLETED 124 participants

Antibiotic Prophylaxis Before Percutaneous Gastrostomy

University of Washington

NCT01424085

COMPLETED Phase 3 114 participants

Safety and Effectiveness of Granulocyte Transfusions in Resolving Infection in People With Neutropenia (The RING Study)

Carelon Research

NCT00627393

COMPLETED 100 participants

Community - Associated Extended-spectrum Beta-lactamases (ESBL)

University of Pittsburgh

NCT00363220

COMPLETED NA 100 participants

Decreasing Infection In Arthroscopic Shoulder Surgery

McLaren Health Care

NCT02219776

COMPLETED 52 participants

Longitudinal Gene Expression Profiling in Adults After Traumatic Injury

Stanford University

NCT02656459

COMPLETED NA 45 participants

Clinical Experiment of Helicobacter Pylori Transmission

Stanford University

NCT00550368

COMPLETED NA 44 participants

CleanHands Sensor Based System to Improve Hand Hygiene and Reduce Infection

Microsensor Labs

NCT03948672

COMPLETED NA 40 participants

Bioequivalency Study of Clarithromycin Tablets Under Fasting Conditions

Roxane Laboratories

NCT00601315

COMPLETED Phase 2 40 participants

Study to Evaluate the Safety and Efficacy of Telavancin in the Treatment of Gram Positive Bloodstream Infections in Cancer Patients

M.D. Anderson Cancer Center

NCT01321879

COMPLETED Phase 2 32 participants

Sirolimus, Tacrolimus, and Antithymocyte Globulin in Preventing Graft-Versus-Host Disease in Patients Undergoing a Donor Stem Cell Transplant For Hematological Cancer

City of Hope Medical Center

NCT00589563

COMPLETED Phase 3 30 participants

Study of Antimicrobial Activity of Omiganan 1% Gel vs. Chlorhexidine 2% for Topical Skin Antisepsis in Healthy Adult Subjects

Cadence Pharmaceuticals

NCT00608959

COMPLETED Phase 1 24 participants

Pharmacokinetics and Safety of Cefazolin 2g in DUPLEX

B. Braun Medical

NCT01121354

COMPLETED 22 participants

Interactions of Environmental and Human Microbial Communities in a Pediatric Oncology Hospital

St. Jude Children's Research Hospital

NCT02948335

COMPLETED Phase 1 20 participants

Vancomycin Tissue Concentrations by Bier Block or Intravenous Administration

Mayo Clinic

NCT04673877

COMPLETED NA 16 participants

Community Central Line Infection Prevention Trial

Johns Hopkins University

NCT02351258

COMPLETED Phase 2 15 participants

Topical PluroGel PN for the Treatment of Mildly Infected Diabetic Foot Ulcers

PluroGen Therapeutics

NCT02119754

COMPLETED NA 7 participants

Rural Home Hospital: Proof of Concept

Brigham and Women's Hospital

NCT04531280

COMPLETED Early Phase 1 1 participants

Personalized Immunotherapeutic for Antibiotic-resistant Infection

Brigham and Women's Hospital

NCT02508584

COMPLETED NA

Vaccine Therapy in Preventing Flu in Children With Acute Lymphoblastic Leukemia

Roswell Park Cancer Institute

NCT00022035

COMPLETED Phase 1

Ravuconazole in Preventing Fungal Infections in Patients Undergoing Allogeneic Stem Cell Transplantation

National Institutes of Health Clinical Center (CC)

NCT00064311

COMPLETED Phase 1

Chemotherapy and Peripheral Stem Cell Transplantation Followed By Immunotherapy in Treating Patients With Multiple Myeloma

University of Maryland, Baltimore

NCT00046852

Phase Distribution

PhaseTrial count
Phase 1 7
Phase 2 3
Phase 3 3
Phase 4 2

Named interventions

Most-linked intervention names on Infection records (sponsor-reported on ClinicalTrials.gov). Counts are trial links, not unique products.

Usual Care Other
2 trials
chlorhexidine 2% solution Drug
1 trials
omiganan 1% gel Drug
1 trials
11-gene set Other
1 trials
Plurogel PN Drug
1 trials
Initial clinical and laboratory evaluation Other
1 trials
anti-mycoplasma hominis antibodies Biological
1 trials
Gentamicin Collagen sponge Drug
1 trials

US sites by state

Facility locations filed on Infection trials. A trial with sites in several states counts in each.

Pennsylvania 8 trials
Maryland 8 trials
Massachusetts 8 trials
California 7 trials
Texas 5 trials
Minnesota 5 trials
Kentucky 5 trials
Colorado 5 trials

Source: ClinicalTrials.gov, National Library of Medicine. Data is informational only.

What to do with this Infection page

45 registered trials, 10 currently recruiting, is a starting point for a conversation, not a diagnosis or a recommendation.

Trial and recruiting counts reflect ClinicalTrials.gov registry status as of the data vintage above; individual trial eligibility and enrollment status can change.

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This Infection condition card totals 45 registered trials; most-linked intervention Usual Care; top US site state Pennsylvania. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.